补通膏联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病稳定期临床效果  

Clinical Effect of Butong Ointment Combined with Budesonide/Formoterol Dry Powder Inhalation in Treatment of Patients with Chronic Obstructive Pulmonary Disease in Stable Phase

作　　者：刘明[1] 杨慧敏[2] 史飞飞 马慧哲 武蕾[1] 田雪娇 赵丹 杜昕[1] LIU Ming;YANG Hui-min;SHI Fei-fei;MA Hui-zhe;WU Lei;TIAN Xue-jiao;ZHAO Dan;DU Xin(The Second Department of Respiratory Medicine,Hebei Provincial Hospital of Traditional Chinese Medicine,Shijiazhuang 050000,China;Department of General Medicine,the First Hospital of Traditional Chinese Medicine in Baoding,Baoding,Hebei 071000,China;Department of Treating Preventable Diseases,Ningjin County Hospital of Integrated Traditional Chinese and Western Medicine,Ningjin,Hebei 055550,China;the First Department of Internal Medicine,Lincheng County Hospital of Traditional Chinese Medicine,Lincheng,Hebei 054300,China)

机构地区：[1]河北省中医院呼吸二科,石家庄050000 [2]保定市第一中医院普内科,河北保定071000 [3]宁晋县中西医结合医院治未病科,河北宁晋055550 [4]临城县中医医院内一科,河北临城054300

出　　处：《临床误诊误治》2021年第5期32-38,共7页Clinical Misdiagnosis & Mistherapy

基　　金：第三届国医大师传承工作室及全国名中医传承工作室项目(2018-119);河北省中医药管理局科研计划项目(2016029)。

摘　　要：目的观察补通膏联合布地奈德福莫特罗粉吸入剂治疗慢性阻塞性肺疾病(COPD)稳定期的临床效果。方法选取2017年6月—2019年6月诊治的COPD稳定期60例,根据治疗方法不同将其分为观察组和对照组两组各30例,观察组在基础治疗上给予补通膏联合布地奈德福莫特罗粉吸入剂治疗,对照组在基础治疗上给予布地奈德福莫特罗粉吸入剂治疗。比较两组治疗60和120 d后临床效果,治疗前和治疗60、120 d后症状和体征分级量化评分、COPD评估测试(CAT)评分、肺功能指标及炎性因子,以及治疗期间不良反应发生情况。结果治疗60和120 d后,观察组总有效率均高于对照组,差异有统计学意义(P<0.05)。治疗60和120 d后,两组症状和体征分级量化评分及CAT评分均较治疗前降低,观察组症状和体征分级量化评分及CAT评分均低于对照组,差异有统计学意义(P<0.05或P<0.01)。治疗60和120 d后,观察组第1秒用力呼气容积占预计值百分比和第1秒用力呼气容积占用力肺活量百分比均较治疗前升高,且均高于对照组,差异有统计学意义(P<0.05或P<0.01)。治疗60和120 d后,两组血清白细胞介素-6(IL-6)、白细胞介素-8(IL-8)和肿瘤坏死因子-α(TNF-α)均较治疗前降低;治疗120 d后,两组血清IL-6和IL-8均较治疗60 d后降低;治疗60和120 d后,观察组血清IL-6、IL-8及TNF-α均低于对照组,差异有统计学意义(P<0.05或P<0.01)。治疗期间,两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论补通膏联合布地奈德福莫特罗粉吸入剂治疗COPD稳定期患者效果显著,能够改善临床症状、提高肺功能、降低血清炎性因子水平,且安全性好。Objective To observe clinical efficacy of Butong Ointment combined with Budesonide/Formoterol Dry Powder Inhalation in treatment of patients with chronic obstructive pulmonary disease(COPD)in stable phase.Methods A total of 60 COPD patients in stable phase during June 2017 and June 2019 were divided into observation group(n=30)and control group(n=30)according to different treatment methods.Observation group was given Butong Ointment combined with Budesonide/Formoterol Dry Powder Inhalation on the basis of basic treatment,while control group was given Budesonide/Formoterol Dry Powder Inhalation on the basis of basic treatment.Clinical effects after treatment for 60 d and 120 d,symptoms and signs quantification scores(SSQS),COPD assessment test(CAT)scores,pulmonary function parameters and inflammatory factors before treatment and after treatment for 60 d and 120 d were compared between two groups.Incidence rate of adverse effects during treatment was also compared between two groups.Results The total response rate in observation group was significantly higher than that in control group after treatment for 60 d and 120 d(P<0.05).SSQS and CAT scores after treatment for 60 d and 120 d were significantly lower than those before treatment in two groups,and the scores in observation group were significantly lower than those in control group.(P<0.05 or P<0.01).After treatment for 60 d and 120 d,percentages of forced expiratory volume in one second/prediction(FEV1%)and forced expiratory volume in one second/forced vital capacity(FEV1/FVC)in observation group were significantly increased than those before treatment in the same group and control group(P<0.05 or P<0.01).After treatment for 60 d and 120 d,levels of interleukin 6(IL-6),interleukin 8(IL-8)and tumor necrotic factorsα(TNF-α)were significantly lower than those before treatment in two groups..Levels of serum IL-6 and IL-8 were significantly lower after treatment for 120 d than those after treatment for 60 d in two groups;levels of serum IL-6,IL-8 and TNF-αin obse

关 键 词：肺疾病 慢性阻塞性 补通膏 布地奈德福莫特罗粉吸入剂 治疗结果 白细胞介素-6 白细胞介素-8 肿瘤坏死因子-Α 

分 类 号：R563.9[医药卫生—呼吸系统]